Bristol-Myers Squibb announces resubmission of NDA for hep C drug.


Bristol-Myers Squibb has announced that the resubmission of a new drug application for Daclatasvir, which is an investigational NS5A replication complex inhibitor. The FDA will review the drug for use in combination with sofosbuvir when treating chronic hepatitis C genotype 3. The new NDA has amended the first, adding new data from the Phase III ALLY-3 trial which showed positive cure rates when the drugs were used in combination.

Read the source article at

About the Author

Leave a Reply